[Treatment and challenges of bulevirtide in chronic hepatitis D].
Zhonghua Gan Zang Bing Za Zhi
; 30(10): 1026-1028, 2022 Oct 20.
Article
em Zh
| MEDLINE
| ID: mdl-36727226
ABSTRACT
In July of 2020, bulevirtide was conditionally approved for the treatment of adults with compensated chronic hepatitis D. Some clinical studies have evaluated the safety and efficacy of bulevirtide as a treatment option for chronic hepatitis D in recent years. Herein are presented a brief review and an outline.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Hepatite D Crônica
Limite:
Adult
/
Humans
Idioma:
Zh
Ano de publicação:
2022
Tipo de documento:
Article